Forecast

There is no analyst data available for this company.

News Go to news feed

Aiforia: revenue falls 46% in first half, stock drops sharply

Aiforia reports a 46% revenue decline for H1 2026 to EUR 753,000 and an EBITDA loss of EUR 4.7m (previous year: -3.0m). Management attributes the decline mainly to extended implementation times and staggered revenue recognition, but stresses that 98% of revenues are recurring and no clinical customers have churned. The share fell about 13.8% to USD 1.08 after the figures; liquidity stood at EUR 9.9m as of June 30. In June Aiforia secured an EIB venture debt facility of up to EUR 20m and aims for financial independence by the end of 2027. » More on de.investing.com
Aiforia Technologies: revenue rises 24% driven by 68% growth in the clinical segment

Aiforia Technologies reported total revenue growth of 24% year‑on‑year for Q4/2025, supported by a 68% increase in the clinical segment. The company accelerated revenue growth to 45% in H2 2025, reported recurring revenues of more than €2m and invested €6.6m in R&D. Aiforia plans to expand its AI model portfolio and its presence in North America and Europe; the stock rose 6.59% to €1.82 after the figures. » More on de.investing.com